Methylphenidate attenuates signs of evoked neuropathic pain in animal model
Physiol Res. 2023 Dec 29;72(S5):S551-S558.ABSTRACTMethylphenidate is a psychostimulant that increases dopamine and noradrenaline levels. Recent studies have shown that methylphenidate potentiates the effect of morphine and together suppress acute and chronic pain. In clinical practice, methylphenidate has been used as a treatment for ADHD and changes of pain threshold have been noted in these patients. The aim of this study was to determine the effect of methylphenidate in an animal model of peripheral neuropathic pain. Neuropathic pain was modeled by the chronic constriction of the sciatic nerve (CCI) in Wistar rats. We e...
Source: Physiological Research - January 2, 2024 Category: Physiology Authors: K Panu šková L Vod ěrová Š Vaculín Source Type: research
Methylphenidate attenuates signs of evoked neuropathic pain in animal model
Physiol Res. 2023 Dec 29;72(S5):S551-S558.ABSTRACTMethylphenidate is a psychostimulant that increases dopamine and noradrenaline levels. Recent studies have shown that methylphenidate potentiates the effect of morphine and together suppress acute and chronic pain. In clinical practice, methylphenidate has been used as a treatment for ADHD and changes of pain threshold have been noted in these patients. The aim of this study was to determine the effect of methylphenidate in an animal model of peripheral neuropathic pain. Neuropathic pain was modeled by the chronic constriction of the sciatic nerve (CCI) in Wistar rats. We e...
Source: Physiological Research - January 2, 2024 Category: Physiology Authors: K Panu šková L Vod ěrová Š Vaculín Source Type: research
Pharmacokinetics of Long-Acting Methylphenidate: Formulation Differences, Bioequivalence, Interchangeability
ConclusionAdditional pharmacokinetic parameters and consistency in guidelines across the regulatory bodies may improve bioequivalence assessments. Based on our findings, more research is also required to understand whether bioequivalence is an appropriate measure for determining MPH interchangeability. This critical review is suitable for formulation scientists, clinical pharmacologists, and clinicians. (Source: European Journal of Drug Metabolism and Pharmacokinetics)
Source: European Journal of Drug Metabolism and Pharmacokinetics - December 21, 2023 Category: Drugs & Pharmacology Source Type: research
Pharmacotherapy for ADHD in children and adolescents: A summary and overview of different European guidelines
Conclusion: Pharmacological treatment options for ADHD in children and adolescents are effective and generally well-tolerated. Pharmacotherapy for ADHD is always part of a multimodal approach. While there is a considerable consensus among European guidelines on pharmacotherapy for ADHD, notable differences exist, particularly concerning the selection and sequencing of various medications.What is Known:• There is a significant base of evidence for pharmacological treatment for ADHD in children and adolescents.• Pediatricians are often involved in assessment, diagnosis and management of children with ADHD.What is N...
Source: European Journal of Pediatrics - December 14, 2023 Category: Pediatrics Source Type: research
Methylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats
Neuropsychopharmacology, Published online: 12 December 2023; doi:10.1038/s41386-023-01777-zMethylphenidate with or without fluoxetine triggers reinstatement of cocaine seeking behavior in rats (Source: Neuropsychopharmacology)
Source: Neuropsychopharmacology - December 12, 2023 Category: Neurology Authors: Lorissa Lamoureux Joel Beverley Heinz Steiner Michela Marinelli Source Type: research
Lisdexamphetamine versus methylphenidate for paediatric patients with attention-deficit hyperactivity disorder and type 1 diabetes (LAMAinDiab): protocol for a multicentre, randomised cross-over clinical trial in an outpatient telemedicine-supported setting
Introduction
Attention deficit hyperactivity disorder (ADHD) affects 5%–10% of paediatric population and is reportedly more common in children with type 1 diabetes (T1D), exacerbating its clinical course. Proper treatment of ADHD in such patients may thus provide neurological and metabolic benefits. To test this, we designed a non-commercial second phase clinical trial comparing the impact of different pharmacological interventions for ADHD in children with T1D.
Methods and analysis
This is a multicentre, randomised, open-label, cross-over clinical trial in children and adolescents with ADHD and T1D. The trial will ...
Source: BMJ Open - December 12, 2023 Category: General Medicine Authors: Michalak, A., Chrzanowski, J., Kusmierczyk-Kozieł, H., Klejman, E., Błaziak, K., Mianowska, B., Szadkowska, A., Chobot, A. P., Jarosz-Chobot, P., Mysliwiec, M., Makowska, I., Kalenik, A., Zamarlik, M., Wolanczyk, T., Fendler, W., Butwicka, A Tags: Open access, Paediatrics Source Type: research
Association of Psychopharmacological Medication Preference with Autistic Traits and Emotion Regulation in ADHD
CONCLUSIONS: This study highlights emotion regulation difficulties and how different emotional profiles may influence medication selection in children with ADHD.PMID:38076669 | PMC:PMC10698854 (Source: Psychopharmacology Bulletin)
Source: Psychopharmacology Bulletin - December 11, 2023 Category: Psychiatry & Psychology Authors: Burcu Ozbaran Ipek Inal-Kaleli Nurhak Dogan Halil Ibrahim Colak Anil Altunkaya Beyza Ozbaran Sezen Kose Source Type: research
